Global Amblyopia Market is segmented By Treatment Type (Patching, Atropine Drops, Vision Therapy, Surgery), By Disease Type (Strabismic Amblyopia, Refractive Amblyopia, D ....
Market Size in USD
CAGR5.8%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 5.8% |
Market Concentration | Medium |
Major Players | Novartis, Bausch & Lomb, Vivid Vision, Ocumetics Technology Corporation, RevitalVision |
The Global Amblyopia Market is estimated to be valued at USD 8.9 Bn in 2024 and is expected to reach USD 15.9 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5.8% from 2024 to 2031. Amblyopia, commonly known as lazy eye, refers to reduced vision in one or both eyes due to lack of visual stimulation during early childhood development. If left untreated, it can lead to permanently reduced vision. The increasing cases of lazy eye among children and the need for early detection and treatment are major factors contributing to the growth of this market.
The market is witnessing positive trends with growing awareness regarding amblyopia among parents and initiatives by governments worldwide to screen children from ages 3 to 5 years. Various technological advancements in diagnosis and treatment such as new screening tools, prescription lenses, eye patches, and atropine eye drops are further supporting market growth. However, high treatment costs and lack of awareness in developing regions continue to restrain the amblyopia market to some extent.